Insurance Approval for Definitive Proton Therapy for Prostate Cancer

PURPOSE: To determine factors that influence insurance approval for definitive proton therapy (PT) for prostate cancer. MATERIALS AND METHODS: Between 2014 and 2018, 1592 insured patients with localized prostate cancer were evaluated and recommended to undergo definitive PT; 547 patients (34.4%) had...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendenhall, William M., Brooks, Eric D., Smith, Stephanie, Morris, Christopher G., Bryant, Curtis B., Henderson, Randal H., Nichols, Romaine C., McIntyre, Kathy, Klein, Stuart L., Mendenhall, Nancy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768894/
https://www.ncbi.nlm.nih.gov/pubmed/35127974
http://dx.doi.org/10.14338/IJPT-21-00002.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768894/
https://www.ncbi.nlm.nih.gov/pubmed/35127974
http://dx.doi.org/10.14338/IJPT-21-00002.1

Ejemplares similares